Ipsen Licenses Novel Antibody-Drug Conjugate from Foreseen Biotechnology for Cancer Treatment

1. Global Licensing Agreement: Ipsen has entered into an exclusive global licensing agreement with Foreseen Biotechnology for the development and commercialization of FS001, a novel antibody-drug conjugate (ADC) with first-in-class potential for cancer treatment.
2. Target and Mechanism: FS001 targets a novel tumor-associated antigen overexpressed in many solid tumors, playing a critical role in tumor proliferation and metastasis. It utilizes an innovative, stable, and cleavable linker coupled to a potent topoisomerase I inhibitor.
3. Preclinical Efficacy: FS001 has demonstrated preclinical efficacy in multi-drug resistant cancer models and has a favorable safety profile with a wide therapeutic window in animal studies.
4. Development and Commercialization: Ipsen will develop, manufacture, and commercialize FS001, with Foreseen Biotechnology eligible to receive up to $1.03 billion in milestone payments and tiered royalties on global sales contingent upon successful development and regulatory approvals.
5. Phase I Clinical Trial: Ipsen plans to initiate a Phase I clinical trial to evaluate FS001 in selected solid tumor types, aiming to deliver critical new treatments for people living with cancer worldwide.